Last €12.34 EUR
Change Today +0.17 / 1.40%
Volume 0.0
3A9 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 2:02 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

alder biopharmaceuticals inc (3A9) Snapshot

Open
€12.84
Previous Close
€12.17
Day High
€12.84
Day Low
€12.34
52 Week High
06/16/14 - €15.70
52 Week Low
05/28/14 - €7.17
Market Cap
380.0M
Average Volume 10 Days
34.0
EPS TTM
--
Shares Outstanding
30.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALDER BIOPHARMACEUTICALS INC (3A9)

Related News

No related news articles were found.

alder biopharmaceuticals inc (3A9) Related Businessweek News

No Related Businessweek News Found

alder biopharmaceuticals inc (3A9) Details

Alder Biopharmaceuticals Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes various therapeutic antibodies in the United States and Australia. It is developing monoclonal antibodies comprising ALD403, which has completed Phase Ib proof-of-concept trials to target calcitonin gene-related peptide for the prevention of migraine; and Clazakizumab that has completed Phase IIb clinical trials that inhibits the pro-inflammatory cytokine interleukin-6 in the treatment of rheumatoid arthritis and psoriatic arthritis. The company also has preclinical programs in the discovery phase for various indications. Alder Biopharmaceuticals Inc. has a collaboration with Bristol-Myers Squibb Company for the development of Clazakizumab. Alder Biopharmaceuticals Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

76 Employees
Last Reported Date: 08/5/14
Founded in 2002

alder biopharmaceuticals inc (3A9) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $384.7K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $362.4K
Co-Founder, Chief Business Officer, Treasurer...
Total Annual Compensation: $308.4K
Senior Vice President of Translational Medici...
Total Annual Compensation: $354.3K
Compensation as of Fiscal Year 2013.

alder biopharmaceuticals inc (3A9) Key Developments

Alder Biopharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Alder Biopharmaceuticals Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $4.7 million compared to the same amount for the same period in 2013. Revenues in both periods were derived primarily from Alder's collaboration with Bristol-Myers Squibb. Net loss was $7.4 million, or $0.40 per share, compared to a net loss of $5.1 million, or $5.27 per share, for the same period in 2013. The net loss per share calculations for the three months ended June 30, 2014 includes the weighted average impact of preferred shares converting into common shares upon the completion of Alder's initial public offering. The increase in net loss for the 2014 period was due to both increased research and development and general and administrative expenses. Loss from operations was $7.4 million against $5.1 million for the same period a year ago. For the six months, the company reported total revenue of $9.5 million, loss from operations of $12.8 million, net loss of $12.8 million or $1.30 per basic and diluted share against total revenue of $9.3 million, loss from operations of $10.8 million, net loss of $10.8 million or $11.16 per basic and diluted share for the same period a year ago.

Alder Biopharmaceuticals Inc. to Report Q2, 2014 Results on Aug 05, 2014

Alder Biopharmaceuticals Inc. announced that they will report Q2, 2014 results After-Market on Aug 05, 2014

Alder Biopharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

Alder Biopharmaceuticals Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
3A9:GR €12.34 EUR +0.17

3A9 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 3A9.
View Industry Companies
 

Industry Analysis

3A9

Industry Average

Valuation 3A9 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.8x
Price/Book 14.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 23.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALDER BIOPHARMACEUTICALS INC, please visit www.alderbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.